Clinical Reviews in Allergy & Immunology

, Volume 43, Issue 1–2, pp 98–137

Asthma in Children and Adolescents: A Comprehensive Approach to Diagnosis and Management



Asthma is a chronic disease that has a significant impact on quality of life and is particularly important in children and adolescents, in part due to the higher incidence of allergies in children. The incidence of asthma has increased dramatically during this time period, with the highest increases in the urban areas of developed countries. It seems that the incidence in developing countries may follow this trend as well. While our knowledge of the pathophysiology of asthma and the available of newer, safer medication have both improved, the mortality of the disease has undergone an overall increase in the past 30 years. Asthma treatment goals in children include decreasing mortality and improving quality of life. Specific treatment goals include but are not limited to decreasing inflammation, improving lung function, decreasing clinical symptoms, reducing hospital stays and emergency department visits, reducing work or school absences, and reducing the need for rescue medications. Non-pharmacological management strategies include allergen avoidance, environmental evaluation for allergens and irritants, patient education, allergy testing, regular monitoring of lung function, and the use of asthma management plans, asthma control tests, peak flow meters, and asthma diaries. Achieving asthma treatment goals reduces direct and indirect costs of asthma and is economically cost-effective. Treatment in children presents unique challenges in diagnosis and management. Challenges in diagnosis include consideration of other diseases such as viral respiratory illnesses or vocal cord dysfunction. Challenges in management include evaluation of the child’s ability to use inhalers and peak flow meters and the management of exercise-induced asthma.


Asthma Allergies Exercise-induced asthma Pediatric asthma Atopic march Wheezing Viral respiratory infections 


  1. 1.
    Pearce N, Douwes J (2006) The global epidemiology of asthma in children. Int J Tuberc Lung Dis 10:125–132PubMedGoogle Scholar
  2. 2.
    Bateman ED, Hurd SS, Barnes PJ et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143–178PubMedGoogle Scholar
  3. 3.
    New NHLBI (1997) Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute. Lippincott Health Promot Lett 2(1):8–9Google Scholar
  4. 4.
    Expert Panel Report 3 (EPR-3) (2007) Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120:S94–S138Google Scholar
  5. 5.
    Priftis KN, Mantzouranis EC, Anthracopoulos MB (2009) Asthma symptoms and airway narrowing in children growing up in an urban versus rural environment. J Asthma 46:244–251PubMedGoogle Scholar
  6. 6.
    Chang CC, Phinney SD, Halpern GM, Gershwin ME (1993) Asthma mortality: another opinion—is it a matter of life and … bread? J Asthma 30:93–103PubMedGoogle Scholar
  7. 7.
    Dixon AE, Holguin F, Sood A et al (2010) An official American Thoracic Society Workshop report: obesity and asthma. Proc Am Thorac Soc 7:325–335PubMedGoogle Scholar
  8. 8.
    Vollmer WM, Buist AS, Osborne ML (1992) Twenty year trends in hospital discharges for asthma among members of a health maintenance organization. J Clin Epidemiol 45:999–1006PubMedGoogle Scholar
  9. 9.
    Berce V, Potocnik U (2010) Functional polymorphism in CTLA4 gene influences the response to therapy with inhaled corticosteroids in Slovenian children with atopic asthma. Biomarkers 15:158–166PubMedGoogle Scholar
  10. 10.
    Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H (2010) Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 20:179–186PubMedGoogle Scholar
  11. 11.
    Polimanti R, Piacentini S, Moscatelli B, Pellicciotti L, Manfellotto D, Fuciarelli M (2010) GSTA1, GSTO1 and GSTO2 gene polymorphisms in Italian asthma patients. Clin Exp Pharmacol Physiol 37:870–872PubMedGoogle Scholar
  12. 12.
    Piacentini S, Polimanti R, Moscatelli B et al (2010) Glutathione S-transferase gene polymorphisms and air pollution as interactive risk factors for asthma in a multicentre Italian field study: a preliminary study. Ann Hum Biol 37:427–439PubMedGoogle Scholar
  13. 13.
    Vergara CI, Acevedo N, Jimenez S et al (2010) A six-SNP haplotype of ADAM33 is associated with asthma in a population of Cartagena, Colombia. Int Arch Allergy Immunol 152:32–40PubMedGoogle Scholar
  14. 14.
    Hesselmar B, Bergin AM, Park H et al (2010) Interleukin-4 receptor polymorphisms in asthma and allergy: relation to different disease phenotypes. Acta Paediatr 99:399–403PubMedGoogle Scholar
  15. 15.
    Sleiman PM, Flory J, Imielinski M et al (2010) Variants of DENND1B associated with asthma in children. N Engl J Med 362:36–44PubMedGoogle Scholar
  16. 16.
    Via M, De Giacomo A, Corvol H et al (2010) The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clin Exp Allergy 40:582–589PubMedGoogle Scholar
  17. 17.
    Reijmerink NE, Bottema RW, Kerkhof M et al (2010) TLR-related pathway analysis: novel gene-gene interactions in the development of asthma and atopy. Allergy 65:199–207PubMedGoogle Scholar
  18. 18.
    Gao J, Li W, Willis-Owen SA et al (2010) Polymorphisms of PHF11 and DPP10 are associated with asthma and related traits in a Chinese population. Respiration 79:17–24PubMedGoogle Scholar
  19. 19.
    Wang TN, Tseng HI, Kao CC et al (2010) The effects of NOS1 gene on asthma and total IgE levels in Taiwanese children, and the interactions with environmental factors. Pediatr Allergy Immunol 21:1064–1071PubMedGoogle Scholar
  20. 20.
    Jonsson UB, Hakansson LD, Jogi R, Janson C, Venge P (2010) Associations of ECP (eosinophil cationic protein)-gene polymorphisms to allergy, asthma, smoke habits and lung function in two Estonian and Swedish sub cohorts of the ECRHS II study. BMC Pulm Med 10:36PubMedGoogle Scholar
  21. 21.
    Harada M, Hirota T, Jodo AI, et al (2011) TSLP promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol. doi:10.1165/rcmb.2009-0418OC
  22. 22.
    Zhang YG, Huang J, Zhang J et al (2010) RANTES gene polymorphisms and asthma risk: a meta-analysis. Arch Med Res 41:50–58PubMedGoogle Scholar
  23. 23.
    Polk S, Sunyer J, Munoz-Ortiz L et al (2004) A prospective study of Fel d1 and Der p1 exposure in infancy and childhood wheezing. Am J Respir Crit Care Med 170:273–278PubMedGoogle Scholar
  24. 24.
    Wennergren G, Ekerljung L, Alm B, Eriksson J, Lotvall J, Lundback B (2010) Asthma in late adolescence—farm childhood is protective and the prevalence increase has levelled off. Pediatr Allergy Immunol 21:806–813PubMedGoogle Scholar
  25. 25.
    Sheehan WJ, Rangsithienchai PA, Wood RA et al (2010) Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma & Immunology Indoor Allergy/Air Pollution Committee. J Allergy Clin Immunol 125:575–581PubMedGoogle Scholar
  26. 26.
    Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedGoogle Scholar
  27. 27.
    Randolph C (2010) The challenge of asthma in adolescent athletes: exercise induced bronchoconstriction (EIB) with and without known asthma. Adolesc Med State Art Rev 21:44–56, viiiPubMedGoogle Scholar
  28. 28.
    Peroni DG, Pietrobelli A, Boner AL (2010) Asthma and obesity in childhood: on the road ahead. Int J Obes (Lond) 34:599–605Google Scholar
  29. 29.
    Lund TK (2009) Asthma in elite athletes: how do we manage asthma-like symptoms and asthma in elite athletes? Clin Respir J 3:123PubMedGoogle Scholar
  30. 30.
    Stickland MK, Spooner CH, Dryden DM, Rowe BH (2010) The need for standardization in exercise challenge testing for exercise-induced asthma/bronchoconstriction. J Allergy Clin Immunol 126:878–880.e6PubMedGoogle Scholar
  31. 31.
    Rosenthal LA, Avila PC, Heymann PW et al (2010) Viral respiratory tract infections and asthma: the course ahead. J Allergy Clin Immunol 125:1212–1217PubMedGoogle Scholar
  32. 32.
    Jackson DJ, Johnston SL (2010) The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 125:1178–1187, quiz 88–9PubMedGoogle Scholar
  33. 33.
    Sly PD, Kusel M, Holt PG (2010) Do early-life viral infections cause asthma? J Allergy Clin Immunol 125:1202–1205PubMedGoogle Scholar
  34. 34.
    Bizzintino J, Lee WM, Laing IA et al (2011) Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J. doi:10.1183/09031936.00092410
  35. 35.
    Jackson DJ (2010) The role of rhinovirus infections in the development of early childhood asthma. Curr Opin Allergy Clin Immunol 10:133–138PubMedGoogle Scholar
  36. 36.
    Johnston SL, Pattemore PK, Sanderson G et al (1996) The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 154:654–660PubMedGoogle Scholar
  37. 37.
    McBride JT (1999) Pulmonary function changes in children after respiratory syncytial virus infection in infancy. J Pediatr 135:28–32PubMedGoogle Scholar
  38. 38.
    Dimova-Yaneva D, Russell D, Main M, Brooker RJ, Helms PJ (2004) Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy 34:555–558PubMedGoogle Scholar
  39. 39.
    Sigurs N, Gustafsson PM, Bjarnason R et al (2005) Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 171:137–141PubMedGoogle Scholar
  40. 40.
    Sigurs N, Aljassim F, Kjellman B et al (2010) Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65:1045–1052PubMedGoogle Scholar
  41. 41.
    Naclerio RM, Meier HL, Kagey-Sobotka A et al (1983) Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 128:597–602PubMedGoogle Scholar
  42. 42.
    Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A (2002) Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 110:85–95PubMedGoogle Scholar
  43. 43.
    Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A (2003) Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 112:S89–S95PubMedGoogle Scholar
  44. 44.
    Ducharme FM, Zemek RL, Chalut D et al (2011) Written action plan in pediatric emergency room improves asthma prescribing, adherence and control. Am J Respir Crit Care Med 183:195–203PubMedGoogle Scholar
  45. 45.
    Sapien RE, Fullerton-Gleason L, Allen N (2004) Teaching school teachers to recognize respiratory distress in asthmatic children. J Asthma 41:739–743PubMedGoogle Scholar
  46. 46.
    Byrnes CA, Dinarevic S, Shinebourne EA, Barnes PJ, Bush A (1997) Exhaled nitric oxide measurements in normal and asthmatic children. Pediatr Pulmonol 24:312–318PubMedGoogle Scholar
  47. 47.
    Mattes J, Storm van’s Gravesande K, Reining U et al (1999) NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J 13:1391–1395PubMedGoogle Scholar
  48. 48.
    Warke TJ, Fitch PS, Brown V et al (2002) Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 57:383–387PubMedGoogle Scholar
  49. 49.
    Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F (1997) Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr 131:381–385PubMedGoogle Scholar
  50. 50.
    del Giudice MM, Brunese FP, Piacentini GL et al (2004) Fractional exhaled nitric oxide (FENO), lung function and airway hyperresponsiveness in naive atopic asthmatic children. J Asthma 41:759–765PubMedGoogle Scholar
  51. 51.
    Bastain TM, Islam T, Berhane KT et al (2011) Exhaled nitric oxide, susceptibility and new-onset asthma in the children’s health study. Eur Respir J. doi:10.1183/09031936.00021210
  52. 52.
    Korn S, Telke I, Kornmann O, Buhl R (2011) Measurement of exhaled nitric oxide: comparison of different analysers. Respirology 15:1203–1208Google Scholar
  53. 53.
    Caudri D, Wijga AH, Hoekstra MO et al (2010) Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE. Thorax 65:801–807PubMedGoogle Scholar
  54. 54.
    Pedrosa M, Cancelliere N, Barranco P, Lopez-Carrasco V, Quirce S (2010) Usefulness of exhaled nitric oxide for diagnosing asthma. J Asthma 47:817–821PubMedGoogle Scholar
  55. 55.
    Sandrini A, Taylor DR, Thomas PS, Yates DH (2010) Fractional exhaled nitric oxide in asthma: an update. Respirology 15:57–70PubMedGoogle Scholar
  56. 56.
    Shields MD, Brown V, Stevenson EC et al (1999) Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clin Exp Allergy 29:1382–1389PubMedGoogle Scholar
  57. 57.
    Peona V, De Amici M, Quaglini S et al (2010) Serum eosinophilic cationic protein: is there a role in respiratory disorders? J Asthma 47:131–134PubMedGoogle Scholar
  58. 58.
    Ahlstedt S (1995) Clinical application of eosinophilic cationic protein in asthma. Allergy Proc 16:59–62PubMedGoogle Scholar
  59. 59.
    Perng DW, Huang HY, Lee YC, Perng RP (2004) Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. Chest 125:1693–1699PubMedGoogle Scholar
  60. 60.
    Basyigit I, Yildiz F, Kacar Ozkara S, Boyaci H, Ilgazli A, Ozkarakas O (2004) Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology 9:514–520PubMedGoogle Scholar
  61. 61.
    Kocak AK, Bor O, Yildiz B, Erdogan L, Us T (2006) T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment. Allergy Asthma Proc 27:371–377PubMedGoogle Scholar
  62. 62.
    Randolph TG, Rollins JP (1950) Adrenocorticotropic hormone (ACTH) its effect in bronchial asthma and ragweed hay fever. Ann Allergy 8:149–162PubMedGoogle Scholar
  63. 63.
    Rose B, Pare JA et al (1950) Preliminary report on adrenocorticotrophic hormone in asthma. Can Med Assoc J 62:6–9PubMedGoogle Scholar
  64. 64.
    Mellon M, Leflein J, Walton-Bowen K, Cruz-Rivera M, Fitzpatrick S, Smith JA (2000) Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 162:593–598PubMedGoogle Scholar
  65. 65.
    Allen DB, Mullen M, Mullen B (1994) A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 93:967–976PubMedGoogle Scholar
  66. 66.
    Balfour-Lynn L (1986) Growth and childhood asthma. Arch Dis Child 61:1049–1055PubMedGoogle Scholar
  67. 67.
    Balfour-Lynn L (1987) Effect of asthma on growth and puberty. Pediatrician 14:237–241PubMedGoogle Scholar
  68. 68.
    Russell G (1994) Childhood asthma and growth—a review of the literature. Respir Med 88 Suppl A:31–36, discussion 6–7PubMedGoogle Scholar
  69. 69.
    Chang CC, Tam AY (1991) Suppression of adrenal function in children on inhaled steroids. J Paediatr Child Health 27:232–234PubMedGoogle Scholar
  70. 70.
    Doull IJ, Freezer NJ, Holgate ST (1995) Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 151:1715–1719PubMedGoogle Scholar
  71. 71.
    Goldstein DE, Konig P (1983) Effect of inhaled beclomethasone dipropionate on hypothalamic–pituitary–adrenal axis function in children with asthma. Pediatrics 72:60–64PubMedGoogle Scholar
  72. 72.
    Boorsma M, Andersson N, Larsson P, Ullman A (1996) Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 9:1427–1432PubMedGoogle Scholar
  73. 73.
    Lemanske RF Jr, Busse WW (2010) The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 126:449–452PubMedGoogle Scholar
  74. 74.
    Alton EW, Norris AA (1996) Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 98:S102–S105, discussion S5–6PubMedGoogle Scholar
  75. 75.
    Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT (1991) Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690–694PubMedGoogle Scholar
  76. 76.
    Martin RM, Wilton LV, Mann RD (1999) Prevalence of Churg–Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 8:179–189PubMedGoogle Scholar
  77. 77.
    Kopriva F, Sobolova L, Szotkowska J, Zapalka M (2004) Treatment of chronic cough in children with montelukast, a leukotriene receptor antagonist. J Asthma 41:715–720PubMedGoogle Scholar
  78. 78.
    Kelsay K (2009) Assessing risk: data from montelukast clinical trials. J Allergy Clin Immunol 124:697–698PubMedGoogle Scholar
  79. 79.
    Ling M, Long AA (2010) Pet dander and difficult-to-control asthma: therapeutic options. Allergy Asthma Proc 31:385–391PubMedGoogle Scholar
  80. 80.
    Shimizu T, Nishihira J, Watanabe H, Abe R, Ishibashi T, Shimizu H (2004) Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy 34:103–109PubMedGoogle Scholar
  81. 81.
    Charlesworth EN, Massey WA, Kagey-Sobotka A, Norman PS, Lichtenstein LM (1992) Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 262:964–970PubMedGoogle Scholar
  82. 82.
    D’Amato G, Liccardi G, Noschese P, Salzillo A, D’Amato M, Cazzola M (2004) Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets Inflamm Allergy 3:227–229PubMedGoogle Scholar
  83. 83.
    Gendo K, Lodewick MJ (2005) Asthma economics: focusing on therapies that improve costly outcomes. Curr Opin Pulm Med 11:43–50PubMedGoogle Scholar
  84. 84.
    Lewis RV, Lofthouse C (1993) Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf 9:272–279PubMedGoogle Scholar
  85. 85.
    Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS (1999) The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 103:615–621PubMedGoogle Scholar
  86. 86.
    Ihre E, Larsson K (1990) Airways responses to ipratropium bromide do not vary with time in asthmatic subjects. Studies of interindividual and intraindividual variation of bronchodilatation and protection against histamine-induced bronchoconstriction. Chest 97:46–51PubMedGoogle Scholar
  87. 87.
    Ueno O, Lee LN, Wagner PD (1989) Effect of N-acetylcysteine on gas exchange after methacholine challenge and isoprenaline inhalation in the dog. Eur Respir J 2:238–246PubMedGoogle Scholar
  88. 88.
    Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME (2010) Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev 9:721–743PubMedGoogle Scholar
  89. 89.
    Campbell LM (2002) From adrenaline to formoterol: advances in beta-agonist therapy in the treatment of asthma. Int J Clin Pract 56:783–790PubMedGoogle Scholar
  90. 90.
    Konig P, Hordvik NL, Serby CW (1984) Fenoterol in exercise-induced asthma. Effect of dose on efficacy and duration of action. Chest 85:462–464PubMedGoogle Scholar
  91. 91.
    Walker SB, Bierman CW, Pierson WE, Shapiro GG, Furukawa CT, Mingo TS (1986) Bitolterol mesylate in exercise-induced asthma. J Allergy Clin Immunol 77:32–36PubMedGoogle Scholar
  92. 92.
    Francis PW, Krastins IR, Levison H (1980) Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm. Pediatrics 66:103–108PubMedGoogle Scholar
  93. 93.
    Sly RM, O’Brien SR (1982) Effect of oral terbutaline on exercise-induced asthma. Ann Allergy 48:151–155PubMedGoogle Scholar
  94. 94.
    Debelic M, Stechert R (1988) Exercise-induced asthma—protection with disodium cromoglycate alone and in combination with fenoterol. Monatsschr Kinderheilkd 136:448–452PubMedGoogle Scholar
  95. 95.
    Patel KR, Wall RT (1986) Dose-duration effect of sodium cromoglycate aerosol in exercise-induced asthma. Eur J Respir Dis 69:256–260PubMedGoogle Scholar
  96. 96.
    Merland N, Cartier A, L’Archeveque J, Ghezzo H, Malo JL (1988) Theophylline minimally inhibits bronchoconstriction induced by dry cold air inhalation in asthmatic subjects. Am Rev Respir Dis 137:1304–1308PubMedGoogle Scholar
  97. 97.
    Thomson NC, Patel KR, Kerr JW (1978) Sodium cromoglycate and ipratropium bromide in exercise-induced asthma. Thorax 33:694–699PubMedGoogle Scholar
  98. 98.
    Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP (1993) Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med 87:439–444PubMedGoogle Scholar
  99. 99.
    Kemp JP (2009) Exercise-induced bronchoconstriction: the effects of montelukast, a leukotriene receptor antagonist. Ther Clin Risk Manag 5:923–933PubMedGoogle Scholar
  100. 100.
    Tanser AR, Elmes J (1980) A controlled trial of ketotifen in exercise-induced asthma. Br J Dis Chest 74:398–402PubMedGoogle Scholar
  101. 101.
    Barnes PJ, Wilson NM, Brown MJ (1981) A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax 36:726–730PubMedGoogle Scholar
  102. 102.
    Foresi A, Corbo GM, Ciappi G, Valente S, Polidori G (1987) Effect of two doses of inhaled diltiazem on exercise-induced asthma. Respiration 51:241–247PubMedGoogle Scholar
  103. 103.
    Patel KR (1981) Calcium antagonists in exercise-induced asthma. Br Med J (Clin Res Ed) 282:932–933Google Scholar
  104. 104.
    Zielinski J, Chodosowska E (1977) Exercise-induced bronchoconstriction in patients with bronchial asthma. Its prevention with an antihistaminic agent. Respiration 34:31–35PubMedGoogle Scholar
  105. 105.
    Turner MW, Yalcin I, Soothill JF et al (1984) In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen. Clin Allergy 14:221–231PubMedGoogle Scholar
  106. 106.
    Hedlin G, Heilborn H, Lilja G et al (1995) Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96:879–885PubMedGoogle Scholar
  107. 107.
    Hedlin G, Graff-Lonnevig V, Heilborn H et al (1991) Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 87:955–964PubMedGoogle Scholar
  108. 108.
    Sundin B, Lilja G, Graff-Lonnevig V et al (1986) Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 77:478–487PubMedGoogle Scholar
  109. 109.
    Lowenstein H, Graff-Lonnevig V, Hedlin G et al (1986) Immunotherapy with cat- and dog-dander extracts. III. Allergen-specific immunoglobulin responses in a 1-year double-blind placebo study. J Allergy Clin Immunol 77:497–505PubMedGoogle Scholar
  110. 110.
    Hedlin G, Graff-Lonnevig V, Heilborn H et al (1986) Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 77:488–496PubMedGoogle Scholar
  111. 111.
    Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J (1990) Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 85:460–472PubMedGoogle Scholar
  112. 112.
    Frankland AW, Augustin R (1954) Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 266:1055–1057PubMedGoogle Scholar
  113. 113.
    Frankland AW, Augustin R (1962) Grass pollen antigens effective in treatment. Clin Sci 23:95–102PubMedGoogle Scholar
  114. 114.
    Leynadier F, Banoun L, Dollois B et al (2001) Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 31:988–996PubMedGoogle Scholar
  115. 115.
    Johnstone DE (1957) Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma. AMA J Dis Child 94:1–5PubMedGoogle Scholar
  116. 116.
    Mirone C, Albert F, Tosi A et al (2004) Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 34:1408–1414PubMedGoogle Scholar
  117. 117.
    Gonzalez P, Florido F, Saenz de San Pedro B, de la Torre F, Rico P, Martin S (2002) Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol 12:263–271PubMedGoogle Scholar
  118. 118.
    Bousquet J, Hejjaoui A, Clauzel AM et al (1988) Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 82:971–977PubMedGoogle Scholar
  119. 119.
    Ferreira MB, Santos AS, Pregal AL et al (2001) Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 33:315–318Google Scholar
  120. 120.
    Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF (2003) A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 167:528–533PubMedGoogle Scholar
  121. 121.
    Ramsay CF, Pearson D, Mildenhall S, Wilson AM (2011) Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 66:7–11PubMedGoogle Scholar
  122. 122.
    Nelson KA, Smith SR, Trinkaus K, Jaffe DM (2008) Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care 24:21–27PubMedGoogle Scholar
  123. 123.
    Davis PA, Chang C, Hackman RM, Stern JS, Gershwin ME (1998) Acupuncture in the treatment of asthma: a critical review. Allergol Immunopathol (Madr) 26:263–271Google Scholar
  124. 124.
    Torres-Llenza V, Bhogal S, Davis M, Ducharme F (2010) Use of complementary and alternative medicine in children with asthma. Can Respir J 17:183–187PubMedGoogle Scholar
  125. 125.
    Li XM (2009) Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol 9:161–167PubMedGoogle Scholar
  126. 126.
    Davis PA, Gold EB, Hackman RM, Stern JS, Gershwin ME (1998) The use of complementary/alternative medicine for the treatment of asthma in the United States. J Investig Allergol Clin Immunol 8:73–77PubMedGoogle Scholar
  127. 127.
    Corren J, Busse W, Meltzer EO et al (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181:788–796PubMedGoogle Scholar
  128. 128.
    Tomkinson A, Tepper J, Morton M et al (2010) Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 65:69–77PubMedGoogle Scholar
  129. 129.
    Holgate ST (2004) Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 28:152–157PubMedGoogle Scholar
  130. 130.
    Qiu Z, Fujimura M, Kurashima K, Nakao S, Mukaida N (2004) Enhanced airway inflammation and decreased subepithelial fibrosis in interleukin 6-deficient mice following chronic exposure to aerosolized antigen. Clin Exp Allergy 34:1321–1328PubMedGoogle Scholar
  131. 131.
    Antoniu SA (2010) MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 12:233–239PubMedGoogle Scholar
  132. 132.
    Quarcoo D, Weixler S, Joachim RA et al (2004) Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 34:1314–1320PubMedGoogle Scholar
  133. 133.
    Randolph AG, Lange C, Silverman EK et al (2004) The IL12B gene is associated with asthma. Am J Hum Genet 75:709–715PubMedGoogle Scholar
  134. 134.
    Yang G, Volk A, Petley T et al (2004) Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28:224–232PubMedGoogle Scholar
  135. 135.
    Gallagher G, Eskdale J, Jordan W et al (2004) Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 4:615–626PubMedGoogle Scholar
  136. 136.
    Babu KS, Davies DE, Holgate ST (2004) Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 24:583–597, v–viPubMedGoogle Scholar
  137. 137.
    Forssmann U, Hartung I, Balder R et al (2004) n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. J Immunol 173:3456–3466PubMedGoogle Scholar
  138. 138.
    Warner RL, Lukacs NW, Shapiro SD et al (2004) Role of metalloelastase in a model of allergic lung responses induced by cockroach allergen. Am J Pathol 165:1921–1930PubMedGoogle Scholar
  139. 139.
    Mukhopadhyay S, Sypek J, Tavendale R et al (2010) Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults. J Allergy Clin Immunol 126:70–76.e16PubMedGoogle Scholar
  140. 140.
    Singh D, Petavy F, Macdonald AJ, Lazaar AL, O’Connor BJ (2010) The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 11:26PubMedGoogle Scholar
  141. 141.
    Coyle AJ, Page CP, Atkinson L, Sjoerdsma K, Touvay C, Metzger WJ (1989) Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol 84:960–967PubMedGoogle Scholar
  142. 142.
    Knauer KA, Lichtenstein LM, Adkinson NF Jr, Fish JE (1981) Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med 304:1404–1407PubMedGoogle Scholar
  143. 143.
    Lupinetti MD, Sheller JR, Catella F, Fitzgerald GA (1989) Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. Am Rev Respir Dis 140:932–935PubMedGoogle Scholar
  144. 144.
    Szczeklik A, Schmitz-Schumann M, Krzanowski M, Virchow C Sr (1991) Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma. Clin Exp Allergy 21:411–415PubMedGoogle Scholar
  145. 145.
    Hayashi N, Chihara J, Kobayashi Y et al (1994) Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int Arch Allergy Immunol 104(Suppl 1):57–59PubMedGoogle Scholar
  146. 146.
    Deuel TF, Huang JS (1984) Platelet-derived growth factor. Structure, function, and roles in normal and transformed cells. J Clin Invest 74:669–676PubMedGoogle Scholar
  147. 147.
    Ross R, Raines EW, Bowen-Pope DF (1986) The biology of platelet-derived growth factor. Cell 46:155–169PubMedGoogle Scholar
  148. 148.
    Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedGoogle Scholar
  149. 149.
    Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587–592PubMedGoogle Scholar
  150. 150.
    Tsicopoulos A, Lassalle P, Joseph M et al (1988) Effect of disodium cromoglycate on inflammatory cells bearing the Fc epsilon receptor type II (Fc epsilon RII). Int J Immunopharmacol 10:227–236PubMedGoogle Scholar
  151. 151.
    Thorel T, Joseph M, Tsicopoulos A, Tonnel AB, Capron A (1988) Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. Int Arch Allergy Appl Immunol 85:232–237PubMedGoogle Scholar
  152. 152.
    De Vos C, Joseph M, Leprevost C et al (1989) Inhibition of human eosinophil chemotaxis and of the IgE-dependent stimulation of human blood platelets by cetirizine. Int Arch Allergy Appl Immunol 88:212–215PubMedGoogle Scholar
  153. 153.
    Clifford RL, Knox AJ (2009) Vitamin D—a new treatment for airway remodelling in asthma? Br J Pharmacol 158:1426–1428PubMedGoogle Scholar
  154. 154.
    Palma-Carlos AG, Palma-Carlos ML, Santos MC, Melo A (1995) Cytokines and adhesion molecules in respiratory allergy. Allerg Immunol (Paris) 27:178–181Google Scholar
  155. 155.
    Scurati S, Frati F, Passalacqua G, Puccinelli P, Hilaire C, Incorvaia C (2010) Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence 4:141–145PubMedGoogle Scholar
  156. 156.
    Ciprandi G, Cadario G, Di Gioacchino GM et al (2010) Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc 31:227–231PubMedGoogle Scholar
  157. 157.
    D’Anneo RW, Bruno ME, Falagiani P (2010) Sublingual allergoid immunotherapy: a new 4-day induction phase in patients allergic to house dust mites. Int J Immunopathol Pharmacol 23:553–560PubMedGoogle Scholar
  158. 158.
    Ferres J, Justicia JL, Garcia MP, Munoz-Tuduri M, Alva V (2011) Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). doi:10.1016/j.aller.2010.01.008
  159. 159.
    Leonardi S, Arena A, Bruno ME et al (2010) Olea sublingual allergoid immunotherapy administered with two different treatment regimens. Allergy Asthma Proc 31:e25–e29PubMedGoogle Scholar
  160. 160.
    Bufe A, Eberle P, Franke-Beckmann E et al (2009) Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123:167–173.e7PubMedGoogle Scholar
  161. 161.
    Focke M, Swoboda I, Marth K, Valenta R (2010) Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 40:385–397PubMedGoogle Scholar
  162. 162.
    Melen E, Himes BE, Brehm JM et al (2010) Analyses of shared genetic factors between asthma and obesity in children. J Allergy Clin Immunol 126:631–637.e1–8PubMedGoogle Scholar
  163. 163.
    Vollmer WM, Swain MC (2002) Role of the specialist in the treatment of asthma. Curr Opin Allergy Clin Immunol 2:189–194PubMedGoogle Scholar
  164. 164.
    Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H (2010) Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma 47:257–262PubMedGoogle Scholar
  165. 165.
    Vollmer WM, Markson LE, O’Connor E, Frazier EA, Berger M, Buist AS (2002) Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 165:195–199PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Allergy, Asthma and Immunology, Nemours Children’s HospitalThomas Jefferson UniversityWilmingtonUSA

Personalised recommendations